查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464750

先天性高胰岛素血症治疗药物市场：按适应症类型、治疗方法、给药途径、分销管道和最终用户划分 - 全球预测 2024-2030

Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年先天性高胰岛素血症治疗药物市场规模为1.8253亿美元，2024年达1.922亿美元，2030年达2.6764亿美元，复合年增长率为5.61%。

先天性高胰岛素血症（CHI）是一种复杂的病理，其特征是婴幼儿和儿童胰岛素分泌过多，导致严重低血糖。 CHI 的治疗选择是多方面的，旨在将血糖值维持在正常范围内并预防低血糖发作。其中包括二氮嗪、Octreotide、兰瑞肽等新药等药物治疗，以及严重病例的手术介入。扩大 CHI 治疗选择的主要因素包括诊断技术的进步、对疾病遗传和分子基础的了解的加深以及针对胰岛素分泌特定途径的新型药物的开发。然而，CHI的治疗有挑战，包括二氮嗪可能产​​生液体储存和Octreotide胃肠道症状等副作用，以及症状缓解不完全和低血糖復发的风险。应对这些挑战需要继续研究更有针对性和微创的治疗策略、基于基因分析的个人化医疗以及开发更有效和更安全的药物。可以即时调节胰岛素产生和分泌的人工胰臟系统的出现，为管理 CHI 提供了突破性方法，并为 CHI 提供了先进的治疗方法。

主要市场统计
基准年[2023] 1.8253 亿美元
预测年份 [2024] 1.922 亿美元
预测年份 [2030] 2.6764亿美元
复合年增长率（%） 5.61%

适应症类型 治疗非典型 CHI 需要个别化方法

非典型先天性高胰岛素血症是 CHI 患者的一个子集，具有不常见的基因突变，其症状和严重程度各不相同。这种形式的疾病通常需要结合药物治疗和监测策略的灵活治疗方法。瀰漫性先天性胰岛素分泌过多的特征是整个胰臟胰岛素细胞的异常行为，需要全身性治疗方法。由于细胞受累的广泛性，手术是最后的手段，药物治疗（包括二氮嗪和Octreotide）是主要治疗方法。局部先天性高胰岛素血症的特征是胰臟内局部存在异常细胞。作为一种治疗策略，首选手术切除受影响区域，并且有可能治癒。诊断影像和手术技术的进步极大地改善了局部CHI 的治疗结果。

最终用户医院需要对先天性高胰岛素血症进行多种治疗

对于需要小手术介入或门诊手术的较轻的先天性高胰岛素血症病例，首选门诊手术中心 (ASC)。 ASC 对患者和看护者很有吸引力，因为它们高效、成本低且出院时间短。 ASC 正在配备先进的医疗技术，现在能够提供以前只能在医院提供的各种服务。医院是治疗严重先天性高胰岛素血症病例的主要选择，特别是需要复杂手术介入或加护治疗的病例。医院提供一站式综合护理，包括诊断、手术和术后护理。该医院拥有广泛的设备和专家，非常适合处理更复杂的先天性高胰岛素血症病例。选择专科诊所对先天性高胰岛素血症的治疗进行专门治疗，特别是在持续治疗和介入后追踪方面。这些诊所通常提供高水准的专业知识和个人化的护理计划。

区域洞察

在美洲，先天性高胰岛素疾病市场十分强劲，尤其是在美国，该市场非常注重研究和开发，导致先进治疗方法的采用率很高，并且大型製药企业积极进入。该地区的公司正在投资各种研发 (R&D) 活动，以支持引进先进的先天性高胰岛素血症治疗方法。亚太地区的特点是在意识提高和医疗基础设施改善的推动下实现快速增长，特别是在中国等国家和医疗保健领域。中东和非洲在医疗保健的取得和品质方面存在差异。欧洲公司在该市场占有重要地位，这表明该地区对创新治疗方法和国际合作的开放态度。政府对研究活动的支持扩大了该地区医院和专科诊所的研究活动。

FPNV定位矩阵

FPNV定位矩阵对于评估先天性高胰岛素血症药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对先天性高胰岛素血症治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.先天性高胰岛素血症治疗药物市场规模及预测如何？

2.先天性高胰岛素血症治疗药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.先天性高胰岛素血症治疗药物市场的技术趋势和法规结构是什么？

4.先天性高胰岛素血症治疗药物市场主要供应商的市场占有率是多少？

5.进入先天性高胰岛素血症药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 先天性高胰岛素血症盛行率增加
      • 政府努力促进先天性高胰岛素血症的诊断
    • 抑制因素
      • 先天性高胰岛素血症的报销有限
    • 机会
      • 持续研究和开发以推进先天性高胰岛素血症的治疗
      • 治疗先天性高胰岛素血症的药物核准进展
    • 任务
      • 诊断挑战和可能的治疗併发症
  • 市场区隔分析
    • 适应症类型：非典型CHI的治疗需要更个人化的方法
    • 最终使用者：先天性高胰岛素血症在医院需要多种治疗方法
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章先天性高胰岛素血症治疗药物市场（依适应症类型）

  • 非典型先天性高胰岛素血症
  • 瀰漫性先天性高胰岛素血症
  • 局部先天性高胰岛素血症

第七章先天性高胰岛素血症治疗药物市场（依治疗）

  • 膳食管理
  • 药物
  • 手术治疗

第八章先天性高胰岛素血症治疗药物市场：依给药途径

  • 口服
  • 胃肠外的

第九章先天性高胰岛素血症治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第10章先天性高胰岛素血症治疗药物市场：依最终使用者分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章 北美和南美先天性高胰岛素血症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区先天性高胰岛素血症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲先天性高胰岛素血症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • C-Path 和先天性高胰岛素症国际宣布资料共用协议
    • Zealand Pharma 向美国FDA 提交用于治疗先天性高胰岛素血症的升糖素新药申请
    • Rhythm Pharmaceuticals 宣布收购 Xinvento BV 和临床实验药物组合
  • 战略分析和建议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F97DD5A7D994

[192 Pages Report] The Congenital Hyperinsulinism Treatment Market size was estimated at USD 182.53 million in 2023 and expected to reach USD 192.20 million in 2024, at a CAGR 5.61% to reach USD 267.64 million by 2030.

Congenital hyperinsulinism (CHI) is a complex condition characterized by excessive insulin production in infants and children, leading to severe hypoglycemia. CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.

KEY MARKET STATISTICS
Base Year [2023] USD 182.53 million
Estimated Year [2024] USD 192.20 million
Forecast Year [2030] USD 267.64 million
CAGR (%) 5.61%

Indication Type: Need for a more personalized approach to treat Atypical CHI

Atypical congenital hyperinsulinism represents a subset of CHI patients with less common genetic mutations, leading to variable presentation and severity. This form requires flexible, tailored treatment approaches, often involving a combination of medical therapy and monitoring strategies. Diffuse Congenital hyperinsulinism is characterized by insulin cells across the pancreas behaving abnormally, necessitating a systemic treatment approach. Surgery can be a last resort due to the pervasive nature of cell involvement, and medication management, including diazoxide and octreotide, remains the primary treatment. Focal congenital hyperinsulinism is marked by a localized region of abnormal cells within the pancreas. The preferred treatment strategy is surgical removal of the affected area, offering a potential cure. Advances in imaging and surgical techniques have greatly enhanced the treatment outcomes for focal CHI.

End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals

Ambulatory surgery centers (ASCs) are preferred for less severe cases of congenital hyperinsulinism that necessitate minor surgical interventions or outpatient procedures. The efficiency, lower cost, and faster discharge times make ASCs attractive for patients and caregivers. ASCs are increasingly equipped with advanced medical technologies that enable them to offer a range of services that were traditionally available only in hospital settings. Hospitals are the primary choice for managing severe cases of congenital hyperinsulinism, especially those requiring complex surgical interventions or intensive care. They offer comprehensive care, including diagnostics, surgery, and post-operative management, under one roof. Hospitals are equipped with a broad range of facilities and specialists, making them well-suited for handling congenital hyperinsulinism cases with higher levels of complexity. Specialty clinics are chosen for their specialized care in managing congenital hyperinsulinism, particularly for ongoing management and follow-up post-intervention. These clinics often provide a high level of expertise and personalized care plans.

Regional Insights

In the Americas, the congenital hyperinsulinism market is robust, with a high adoption rate of advanced treatments and active participation from leading pharmaceuticals, driven by a strong focus on research and development, particularly in the United States. Companies in the region have invested in various research & development (R&D) activities to support the introduction of advanced congenital hyperinsulinism treatment. The APAC scenario is marked by rapid growth fueled by increasing awareness and improving healthcare infrastructure, especially in countries such as China and India. EMEA presents a mixed environment with strong healthcare systems in Europe facilitating access to treatments and encouraging clinical trials, while the Middle East and Africa grapple with variability in healthcare access and quality. European companies have a significant presence in the market, indicative of the region's openness to innovative treatments and international collaborations. With government support for research activities, the region is witnessing an expansion of congenital hyperinsulinism treatment activities in hospitals & specialty clinics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Congenital Hyperinsulinism Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Congenital Hyperinsulinism Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Congenital Hyperinsulinism Treatment Market, highlighting leading vendors and their innovative profiles. These include Crinetics Pharmaceuticals, Inc., Eiger Biopharmaceuticals Inc., Hanmi Pharmaceutical Company, Hua Medicine (Shanghai) Co., Ltd., Novartis AG, Rezolute, Inc., Rhythm Pharmaceuticals, Inc., Twist Bioscience Corporation, Xeris Biopharma Holdings, Inc., XOMA Corporation, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Congenital Hyperinsulinism Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication Type
    • Atypical Congenital Hyperinsulinism
    • Diffuse Congenital Hyperinsulinism
    • Focal Congenital Hyperinsulinism
  • Treatment
    • Dietary Management
    • Drugs
      • Diazoxide
      • Glucagon
      • Nifedipine
      • Octreotide
    • Surgical Intervention
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-Users
    • Ambulatory Surgery Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Congenital Hyperinsulinism Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Congenital Hyperinsulinism Treatment Market?

3. What are the technology trends and regulatory frameworks in the Congenital Hyperinsulinism Treatment Market?

4. What is the market share of the leading vendors in the Congenital Hyperinsulinism Treatment Market?

5. Which modes and strategic moves are suitable for entering the Congenital Hyperinsulinism Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
      • 5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
      • 5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges and possible complications of the treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
    • 5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Congenital Hyperinsulinism Treatment Market, by Indication Type

  • 6.1. Introduction
  • 6.2. Atypical Congenital Hyperinsulinism
  • 6.3. Diffuse Congenital Hyperinsulinism
  • 6.4. Focal Congenital Hyperinsulinism

7. Congenital Hyperinsulinism Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Dietary Management
  • 7.3. Drugs
  • 7.4. Surgical Intervention

8. Congenital Hyperinsulinism Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Congenital Hyperinsulinism Treatment Market, by End-Users

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Congenital Hyperinsulinism Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Congenital Hyperinsulinism Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
    • 14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
    • 14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 177. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 189. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET S